Meningococcemia screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Changes made per Mahshid's request) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 9: | Line 9: | ||
*State and local health departments should notify the Centers for Disease Control and Prevention (CDC) if resistance to [[ciprofloxacin]] or other agents used for treatment or prophylaxis is detected. | *State and local health departments should notify the Centers for Disease Control and Prevention (CDC) if resistance to [[ciprofloxacin]] or other agents used for treatment or prophylaxis is detected. | ||
*Passive and active surveillance systems are used to monitor meningococcal [[disease]], which is a reportable [[disease]] in the United States. Through a national passive reporting system, state health departments collect and transmit weekly reports of cases to CDC through the National Electronic Telecommunications System for Surveillance (NETSS). | *Passive and active surveillance systems are used to monitor meningococcal [[disease]], which is a reportable [[disease]] in the United States. Through a national passive reporting system, state health departments collect and transmit weekly reports of cases to CDC through the National Electronic Telecommunications System for Surveillance (NETSS). | ||
*The goals of meningococcal surveillance are | *The goals of meningococcal surveillance are: | ||
:* | :*To detect outbreaks of meningococcal [[disease]] so that appropriate control measures can be promptly instituted, and | ||
:* | :*To assess changes in the epidemiology of meningococcal [[disease]] over time to permit the most efficient allocation of resources and formulation of the most effective disease control and prevention policies. | ||
*Meningococcal serogroup surveillance data are important to monitor the impact of quadrivalent meningococcal conjugate [[vaccine]]. Meningococcal serogroup data also help to determine the epidemiologic link between cases in cluster or outbreak situations. | *Meningococcal serogroup surveillance data are important to monitor the impact of quadrivalent meningococcal conjugate [[vaccine]]. | ||
<ref name=CDC>{{cite web | title = The Centers for Disease Control and Prevention(CDC)| url =http://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.html}}</ref> | *Meningococcal serogroup data also help to determine the epidemiologic link between cases in cluster or outbreak situations.<ref name=CDC>{{cite web | title = The Centers for Disease Control and Prevention(CDC)| url =http://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.html}}</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
| Line 21: | Line 22: | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
Latest revision as of 18:03, 18 September 2017
|
Meningococcemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Meningococcemia screening On the Web |
|
American Roentgen Ray Society Images of Meningococcemia screening |
|
Risk calculators and risk factors for Meningococcemia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Routine screening is not recommended for meningococcemia.
Screening
- Routine antimicrobial susceptibility testing of meningococcal isolates is not currently recommended.
- Surveillance of susceptibility patterns in populations should be conducted in order to monitor trends in N. meningitidis susceptibility.
- State and local health departments should notify the Centers for Disease Control and Prevention (CDC) if resistance to ciprofloxacin or other agents used for treatment or prophylaxis is detected.
- Passive and active surveillance systems are used to monitor meningococcal disease, which is a reportable disease in the United States. Through a national passive reporting system, state health departments collect and transmit weekly reports of cases to CDC through the National Electronic Telecommunications System for Surveillance (NETSS).
- The goals of meningococcal surveillance are:
- To detect outbreaks of meningococcal disease so that appropriate control measures can be promptly instituted, and
- To assess changes in the epidemiology of meningococcal disease over time to permit the most efficient allocation of resources and formulation of the most effective disease control and prevention policies.
- Meningococcal serogroup surveillance data are important to monitor the impact of quadrivalent meningococcal conjugate vaccine.
- Meningococcal serogroup data also help to determine the epidemiologic link between cases in cluster or outbreak situations.[1]